Aspira Women’s Health reports Q4 EPS (8c) vs. (30c) last year

Reports Q4 revenue $2.35M vs. $2.13M last year. Newly appointed CEO Mike Buhle stated, “The Aspira team generated record test volume and revenue in a challenging environment in 2024. During a period of transition and change, our sales and operational team remained focused on markets and the medical community we serve. We are deeply committed to meeting the medical needs of millions of women that benefit from the life-saving capabilities of our early detection OvaSuite product.”